A Breath of Fresh Air: Creating Shared Value in the Philippines

Abstract

GlaxoSmithKline (GSK), a multinational pharmaceutical company, has, for many years, produced a medicine for acute management of asthma and chronic obstructive pulmonary disease (COPD). It is predominantly marketed in a multidose inhaler canister that is generally unaffordable for most people living in poor countries. With the goal of concurrently generating economic returns and delivering positive social outcomes, GSK recently re-launched an affordable single-unit dose presentation of this medicine for asthma and COPD sufferer in low socioeconomic communities. The product takes the form of a salbutamol capsule dispensed through a low-cost inhaler device (the product is henceforth referred to..